British police have detained two individuals in connection with a violent attack near a synagogue in Manchester that left three people dead, including the assailant. The incident occurred in the Crumpsall area of Manchester, where law enforcement officers opened fire on the attacker during the confrontation. Authorities confirmed the suspect was shot and killed during the response to what has been described as a horrific attack targeting the Jewish community.
The death toll from the incident has risen to three, with two additional fatalities beyond the attacker. Five other individuals, including a synagogue security guard, sustained injuries during the attack, with three of the wounded reported to be in critical condition. Police indicated the assailant possessed devices that prompted law enforcement's use of firearms, though specific details about these devices have not been disclosed.
Prime Minister Keir Starmer interrupted his participation in the European Political Community summit in Copenhagen to return to the United Kingdom following the attack. Speaking from the airport in Copenhagen, Starmer announced he would chair an emergency Cobra committee meeting upon his arrival in London to address the situation. The Prime Minister emphasized the government's commitment to ensuring the safety of Jewish communities across the nation.
In response to the Manchester incident, British authorities have implemented enhanced security measures at synagogues nationwide. Additional police resources have been deployed around Jewish places of worship as a precautionary measure. The coordinated security response aims to prevent further incidents and maintain public safety while investigations into the Manchester attack continue.
Global medical technology company Convatec has announced plans to establish a new flagship research and development hub in Manchester as part of a £500 million investment in the United Kingdom. The FTSE100-listed firm, which specializes in products for chronic wounds, diabetes, urinary incontinence, and stomas, will relocate its R&D operations from Deeside to Bruntwood SciTech's CityLabs 4.0 facility, scheduled to open in 2027. This strategic move represents a significant commitment to the UK's life sciences sector at a time when several other pharmaceutical companies have been shifting investments overseas.
The new Manchester facility will become one of the largest centers in Convatec's global network, spanning 125,000 square feet across seven storeys in the £42 million CityLabs 4.0 building. Located on Hathersage Road facing the Manchester Royal Infirmary, St Mary's and Royal Manchester Children's Hospital, the state-of-the-art facility will focus on research in four key therapeutic areas: advanced wound care, ostomy care, continence care, and infusion care. The company cited Manchester's "vibrant life sciences ecosystem, which includes leading universities, hospitals, and research institutions" as the primary reason for selecting the location.
Approximately 200 staff will be employed at the new Manchester hub, with most positions transferring from Convatec's existing R&D operation in Deeside, North Wales, which has served as a major research center since 1996. The company emphasized that no redundancies are planned as a consequence of the relocation and that the Deeside manufacturing site will remain unaffected, continuing to employ around 400 workers. The new Manchester facility is approximately 50% larger than the current Deeside operation and has capacity for up to 250 employees, allowing for future expansion.
Convatec's investment comes as part of a broader $1 billion worldwide R&D commitment, with the UK portion representing nearly half of this global initiative. The company, which generated $2.3 billion in revenue last year, typically allocates approximately 5% of its annual revenue to research and development. The relocation to Manchester positions Convatec to leverage the city's concentration of medical research institutions, including neighboring organizations such as the University of Manchester NHS Foundation Trust, biotech company QIAGEN, and MAC Clinical Research, strengthening its pipeline of new products addressing unmet needs in chronic care.